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A B S T R A C T
Background: Although there have been increasing reports of intentional gabapentin misuse, epidemiological
evidence for the phenomenon is limited. The purpose of this study was to determine whether there are phar-
macovigilance abuse signals for gabapentin.
Methods: Using FDA Adverse Events Reporting System reports from January 1, 2005 to December 31, 2015, we
calculated pharmacovigilance signal measures (i.e., reporting odds ratio, proportional reporting ratio, in-
formation component, and empirical Bayes geometric mean) for abuse-related adverse event (AR-AE)-gaba-
pentin pairs. Loglinear modeling assessed the frequency of concurrent reporting of abuse-related and abuse-
specific AEs (AS-AEs) associated with gabapentin. Findings were compared to a positive (pregabalin) and ne-
gative (duloxetine) control.
Results: From 2005–2015 there were 5,951,229 unique AE reports submitted to the FDA including 99,977 for
gabapentin, 73,977 for duloxetine, and 97,813 for pregabalin. Significant drug-AR-AE pair signals involving
gabapentin included: drug abuser, multiple drug overdose, and substance-induced psychotic disorder. Significant drug
AR-AE signals involving gabapentin and pregabalin, but not duloxetine, were: ataxia, dependence, drug abuse,
increased drug tolerance, and overdose. Compared to duloxetine, gabapentin had significantly greater odds of a co-
report for an AS-AE with drug withdrawal syndrome (OR: 6.55), auditory hallucinations (OR: 4.57), delusions (OR:
2.36), euphoric mood (OR: 5.45), ataxia (OR: 2.85), drug abuser (OR: 3.01), aggression (OR: 1.98), psychotic dis-
order (OR: 1.96), and feeling abnormal (OR: 1.31).
Conclusions: We identified abuse-related signals for gabapentin and highlighted several CNS effects that may be
associated with its abuse. Gabapentin prescribers should be aware of the drug’s abuse liability and effects that
may accompany its use.
1. Introduction
Gabapentin is approved by the U.S. Food and Drug Administration
(FDA) for post-herpetic neuralgia and as an anti-epileptic, but is fre-
quently used off-label for non-herpetic pain, mood disorders, and as a
treatment for alcohol withdrawal and alcohol use disorder. In the latest
guidance report for pain treatment, the Centers for Disease Control and
Prevention (CDC) identified gabapentin as a first-line medication for
treating chronic pain (Dowell et al., 2016). Since its market release in
1993, gabapentin was presumed to have no abuse potential, which has
likely led to its extensive off-label prescribing (it is estimated that be-
tween 83–95% of all gabapentin prescriptions are for a non-approved
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use; Hamer et al., 2002; Radley et al., 2006). However, since the first
published report of gabapentin misuse in 1994 (Fischer et al., 1994), a
substantial number of accounts of gabapentin misuse and abuse have
followed. A recent systematic review identified 23 published case stu-
dies and epidemiologic reports of gabapentin misuse/abuse from seven
different countries (Smith et al., 2016).
Evidence on the prevalence of gabapentin misuse (i.e., use in a
manner or for a purpose other than indicated) (World Health
Organization, 2015a) is limited. One study estimated the population
prevalence of gabapentin misuse at 1 % in the United Kingdom (Kapil
et al., 2014). However, three studies estimated the prevalence of ga-
bapentin misuse within substance misuse samples in the United States
and the United Kingdom to be between 15–22% (Baird et al., 2014;
Smith et al., 2015; Wilens et al., 2015). The mechanism by which ga-
bapentin produces analgesic and anticonvulsant effects is unknown,
though it is likely due to an interaction with calcium channels to reduce
neurotransmitter release from neurons in the central nervous system
(Bockbrader et al., 2010). There is a wide spectrum of subjective effects
of gabapentin, particularly when it is not used as intended (e.g., in
larger doses than prescribed), including: dissociation, euphoria, seda-
tion/relaxation/calmness, elevated mood, disinhibition, delirium,
feeling “high,” and feeling drunk (Reeves and Burke, 2014; Reeves and
Ladner, 2014; Satish et al., 2015; Schifano et al., 2011; Vickers Smith
et al., 2018).
Without controlled pharmacological studies to assess gabapentin’s
abuse potential, other available data can be used to estimate the risk of
gabapentin misuse. One such resource is the FDA Adverse Event
Reporting System (FAERS), a publicly available, FDA- maintained da-
tabase in the United States. FAERS is a passive surveillance program to
which post-marketing adverse events (AEs) associated with any drug or
biologic product can be reported. Approximately 5 % of AEs reported to
FAERS are generated voluntarily by health professionals (e.g., physi-
cians, pharmacists, nurses) and consumers (e.g., patients, family
members, lawyers), who can submit AEs via the online submission
system called MedWatch (U.S. Food and Drug Administration, 2016).
The other 95 % of FAERS reports come from voluntary AE reporting to
the drug sponsor or manufacturer, which is then required to forward
the report to the FDA (U.S. Food and Drug Administration, 2016). The
Center for Drug Evaluation and Research, a division of the FDA,
monitors reports and further evaluates concerns identified through
FAERS (Center for Drug Evaluation and Research, 2018a). If there is a
safety concern over a drug or device, the FDA can choose to take reg-
ulatory action, including, but not limited to: updating labeling in-
formation, restricting use, communicating safety information to the
public, or product removal from the market (Center for Drug Evaluation
and Research, 2018a). As of 2016, FAERS has received over 12 million
reports, two million of which were from 2016 alone (U.S. Food and
Drug Administration, 2016).
Pharmacovigilance (PhV), which is the collection, study, detection,
and prevention of drug adverse events, is a useful tool for hypothesis
generation or hypothesis testing of drug-AE pairs, though a theoretical
conceptualization of the drug-AE combination one intends to in-
vestigate is prerequisite (Poluzzi et al., 2012). PhV studies typically use
several assessment measures to detect a “signal” for a particular drug
(World Health Organization, 2015b), which is a previously unknown
possible causal association of an adverse event resulting from taking a
drug (World Health Organization, 2012). Signals are disproportionality
measures based on a 2× 2 contingency table and determine whether a
drug-AE pair occurs more often than expected by comparing signal
values to published thresholds (Bate et al., 1998; Evans et al., 2001;
Szarfman et al., 2002; van Puijenbroek et al., 2002).
We used the FAERS database to calculate signal measures for reports
of gabapentin and abuse-related AEs (AR-AEs) and compared these
findings to a negative and positive control. The AR-AEs of interest were
selected a priori based on effects associated with gabapentin misuse
reflected in the current literature (Schifano et al., 2011; Smith et al.,
2016). Signals of misuse/abuse/addiction may not always be identified
through observation of a single AE at a time (e.g., a report of gaba-
pentin and ataxia does not necessarily indicate abuse); rather, it may be
more useful to examine the joint occurrence of several AEs that are
indicative of drug misuse/abuse/addiction. Therefore, in addition to
the traditional signal measures, we used loglinear modeling to assess
the frequency of concurrent reporting of AEs associated with gaba-
pentin misuse/abuse.
2. Material and methods
2.1. Data source
All FAERS quarterly data from January 1, 2004 to December 31,
2015 were downloaded from the FDA website (Center for Drug
Evaluation and Research, 2018b). However, because pregabalin was
not approved by the FDA until December 30, 2004 (U.S. Food and Drug
Administration, 2005), data from 2004 were excluded. Each quarterly
data set contained 7 data files: (1) patient demographic and adminis-
trative information; (2) drug/biologic information for all medications
reported for the event; (3) all Medical Dictionary for Regulatory Ac-
tivities (MedDRA) terms coded for the adverse event; (4) patient out-
comes for the AE; (5) report sources for the AE; (6) drug therapy start
and end dates for the reported drug(s); and (7) all MedDRA terms for
the reported drug’s indications/diagnoses. For the purposes of this
analysis, only the demographic, drug, and reaction data tables were
used.
We used positive and negative controls with which to compare the
gabapentin findings. Pregabalin, a structural analog of gabapentin with
a similar mechanism of action, has been classified as a Schedule V drug
because of its abuse potential, which made it an ideal candidate for the
positive control. Because duloxetine, a serotonin-norepinephrine re-
uptake inhibitor, has been recommended as a first-line medication for
the treatment of neuropathic pain (Dowell et al., 2016) (similar to ga-
bapentin) but is not a controlled substance and generally has produced
no signal of abuse liability, it was selected as the negative control.
Based on the proposed methodology of Moore et al. (1997) a case/
non-case approach was used, where each drug-AE pair of interest de-
noted a case and all other possible pairs were non-cases. In every FAERS
AE drug file, FDA clinical reviewers assigned role codes to each re-
ported drug and indicated as follows: primary suspect drug (PS), sec-
ondary suspect drug (SS), interacting (I), or concomitant (C). Often,
only PS, SS, and I medications are considered as cases. However, others
have raised concerns about excluding concomitant medications from
among cases, particularly if they are associated with an unexpected
drug-AE association. As explained in the EudraVigilance data analysis
guidelines, “…it is quite often the case that drug-event associations are
not commonly established until knowledge of the potential signal [is]
available” (European Medicines Agency, 2006). Therefore, due to the
historic opinion that gabapentin had no abuse liability it was apt to
include cases where gabapentin was listed as a concomitant medication.
For consistency, cases where pregabalin or duloxetine were listed as
concomitant medications were also included.
2.2. Case identification - drugs
Drug cases (i.e., AE reports [AERs] that included gabapentin,
pregabalin, and/or duloxetine) were identified in the FAERS drug table
using a phonetic algorithm via the soundex function in the R package,
phonics (Howard, 2018). The soundex function was employed to iden-
tify potential drug case matches by both the brand and generic names of
the case drugs. This procedure works through phonetic matching and
can help to reduce the effect of variations in spelling. The second author
manually scanned potential matches identified through the phonetic
algorithm to determine whether they were true cases. All analyses were
conducted in R.
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2.3. Data cleaning
Each AER in FAERS has a unique “ISR (individual safety report)
number,” which can be used to link files across all seven data tables. A
case number also identifies an AER; however, it may encompass several
ISR numbers (AERs) due to follow-up reporting for the same event.
Once the drug files were merged with their corresponding demographic
files by ISR number, we retained the AER in each Case ID series with the
most recent date, according to the FAERS cleaning protocol (Banda
et al., 2016), and duplicates were removed. The demographic/drug file
was then merged with the MedDRA AE file by the ISR number.
2.4. Case identification - AEs
Using several sources (Schwan et al., 2010; Smith et al., 2013), we
created a list of MedDRA preferred terms (PT) that were explicit in-
dications of abuse (e.g., drug diversion, drug addiction) and those that
could be indicative of abuse (e.g., ataxia, falls, euphoric mood, dis-
sociation). Here abuse-related (AR-AE) will be used to incorporate both
explicit abuse MedDRA terms and MedDRA terms that are possible in-
dicators of abuse, while abuse-specific (AS-AE) refers to explicit abuse
terms only. The list was reviewed by a pharmacology expert [SLW] and
a psychiatrist [MRL] and revised until a final list was agreed upon (see
Appendix 1). It should be noted that each AER could, and most often
did, include more than one MedDRA term.
2.5. Signal calculation
Because AE reporting can be affected by many external factors,
cumulative signal measures were calculated (Poluzzi et al., 2012); that
is, data were aggregated over the 11-year study period rather than
calculated quarterly. Descriptive statistics were calculated for each
drug-AR-AE pair. Traditional signal measures include the proportional
reporting ratio (PRR)(Evans et al., 2001), reporting odds ratio (ROR)
(van Puijenbroek et al., 2002), the information component (IC)(Bate
et al., 1998), and the empirical Bayesian geometric mean (EBGM)
(Szarfman et al., 2002). Published criteria for each signal measure are
as follows (Poluzzi et al., 2012):
For ND, which is the number of AERs for any given drug:
PRR: ND≥3, PRR≥ 2, χ2≥4;
ROR: lower limit of 95 % confidence interval> 1;
IC: lower limit of two-sided 95 % credible interval> 0;
EBGM: ND>0, lower limit of one-sided 95 % credible interval> 2.
First, a composite AR-AE variable was created, that is, any AER that
reported at least one of the AR-AEs was coded as 1 and AERs that did
not report any of these AR-AEs were coded as 0. Signal measures were
calculated for each drug-composite AR-AE pair. Then signal measures
were calculated for individual AR-AE-drug pairs. Because the tradi-
tional signal measures differ in their sensitivity and specificity, we
decided that for our purposes, a drug-AE pair would be significant if all
four signal measures met the thresholds described above. The R
package, PhViD (Ahmed and Poncet, 2016), was used to obtain all
signal scores.
2.6. Loglinear analysis
Loglinear models allow for the simultaneous examination of the
association between more than two categorical variables, essentially an
extension of the 2×2 contingency table to a 2×2×…×2 table,
particularly useful when there is more than one response variable. This
type of model can describe the joint distribution of any number of ca-
tegorical factors.
First, a composite abuse-specific (AS-AE) variable was created
where any AER that reported at least one AS-AE was coded as 1 and
AERs that did not were coded as 0. The AS-AEs included: addiction,
dependence, drug abuse, drug dependence, drug diversion, intentional
(drug) misuse, intentional overdose, multiple drug overdose, overdose,
prescription drug use without a prescription, substance abuse, and
substance use. MedDRA terms drug abuser and substance abuser were
not included as AS-AEs because those refer to the social circumstances
surrounding the event. Therefore, information may be provided in the
AER that the individual had a history of drug misuse, but that does not
necessarily indicate that abuse occurred.
Next, loglinear modeling was used to evaluate the association be-
tween the co-occurrence of an AS-AE and each AE that was a possible
indicator of abuse (e.g., ataxia, substance abuser) in AERs for gaba-
pentin and pregabalin, with duloxetine as the referent group. All data
were assumed to have come from Poisson distributions. Further, AERs
that co-indicated any of the case drugs together (e.g., AER with gaba-
pentin and pregabalin; AER with pregabalin and duloxetine) were not
included in the loglinear analysis to reduce potential conflation of ef-
fects.
3. Results
From 2005–2015 there were 5,951,229 unique AERs submitted to
the FDA. Of those, 99,977 included gabapentin, 73,977 included du-
loxetine, and 97,813 included pregabalin. Overall, the general trends
for received AERs for each case drug were increasing, perhaps more
clearly so for pregabalin and gabapentin than for duloxetine (Fig. 1).
Interestingly, AERs for gabapentin, pregabalin, and duloxetine shared
many of the same most frequently reported AEs including drug in-
effectiveness, pain, nausea, fatigue and dizziness (Table 1).
Nearly one-quarter of all gabapentin reports involved at least one
abuse-related AE (22.93 %; Table 2). That percentage was slightly
higher for pregabalin and duloxetine (26.13 and 29.32 %, respectively).
Of all the gabapentin-abuse-related AEs, dizziness was reported most
frequently (5.25 %), followed by falls (4.48 %), and somnolence (3.33
%). Dizziness and somnolence were also the most frequently reported
abuse-related AEs reported for pregabalin (6.59 % and 5.17 %, re-
spectively), while dizziness (8.03 %), drug withdrawal syndrome (6.42
%), and feeling abnormal (5.26 %) were most common for duloxetine.
With regard to AS-AEs, overdose was reported most frequently for all
three drugs (gabapentin: 1.37 %; pregabalin: 0.94 %; duloxetine: 1.05
%). Also in the top five most commonly reported AS-AEs for all three
drugs were: drug abuse (gabapentin: 0.57 %; pregabalin: 0.66 %; du-
loxetine: 0.37 %), intentional drug misuse (gabapentin: 0.55 %; preg-
abalin: 0.55 %; duloxetine: 0.58 %), intentional overdose (gabapentin:
0.50 %; pregabalin: 0.36 %; duloxetine: 0.51 %), and drug dependence
(gabapentin: 0.49 %; pregabalin: 0.59 %; duloxetine: 0.29 %).
When examining signal measures of gabapentin, 30 gabapentin-AE
pairs met published threshold criteria for all four measures (Appendix
2). Likewise, 32 pregabalin-AE pairs and 29 duloxetine-AE pairs met
published signal threshold criteria for all four measures. Significant
signals (i.e., using our more stringent definition) common to all three
drugs included aggression, confusional state, disorientation, dizziness,
drug dependence, drug tolerance, drug withdrawal syndrome, euphoric
mood, fall, feeling abnormal, feeling drunk, gait disturbance, halluci-
nation, visual hallucination, incoherent, intentional drug misuse, in-
tentional overdose, mood altered, off-label use, somnolence, and
thinking abnormal. Significant AE signals unique to gabapentin (i.e.,
not all 4 signals were significant for pregabalin or duloxetine) were:
drug abuser, multiple drug overdose, and substance-induced psychotic
disorder. Significant AE signals with gabapentin and pregabalin, but not
duloxetine (i.e., not all 4 signals were significant for duloxetine), were:
ataxia, dependence, drug abuse, drug tolerance increased, and over-
dose. Only delusion produced a significant AE signal with gabapentin
and duloxetine, but not pregabalin. Gabapentin, pregabalin, and du-
loxetine produced significant signals for both the composite abuse-re-
lated AE variable and the abuse-specific AE variable. Each drug had AS-
AEs that met the significance threshold for one or more of the PhV
measures, but not for all 4. These included: dependence (duloxetine),
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drug abuse (duloxetine), drug diversion (gabapentin and pregabalin),
multiple drug overdose (pregabalin and duloxetine), overdose (dulox-
etine), substance abuse (gabapentin, pregabalin, and duloxetine), and
substance use (gabapentin, pregabalin, and duloxetine).
Approximately 12–19% of all AERs for each drug contained one or
more of the other case drug(s). When the number of reports was re-
duced to exclude overlap between gabapentin, pregabalin, and/or du-
loxetine, the numbers of unique abuse-related reports for each drug
were 3435 for gabapentin, 2906 for pregabalin, and 2052 for dulox-
etine. For gabapentin, somnolence, drug withdrawal syndrome, and
confusional state were most often co-reported with an AS-AE (Table 3).
Somnolence was also the most often co-reported with a pregabalin AS-
AE, while drug withdrawal syndrome had the highest co-reporting with
a duloxetine AS-AE.
Based on results from the loglinear models, compared to the nega-
tive control, duloxetine, gabapentin had over six times the odds of a co-
report of drug abuse (as an AS-AE) and drug withdrawal syndrome;
pregabalin also had increased odds of this simultaneous report com-
pared to duloxetine, though it was not as high as for gabapentin
(Table 4). Gabapentin and pregabalin also had significantly greater
odds of a co-report for an AS-AE with auditory hallucinations (OR: 4.57
and 4.28, respectively), euphoric mood (OR: 5.45 and 2.47, respec-
tively), delusion (OR: 2.36 and 3.33, respectively), and aggression (OR:
1.98 and 2.47, respectively) compared to duloxetine. Interestingly, an
abuse-specific event and drug abuser were reported together with sig-
nificantly increased odds for gabapentin compared to duloxetine, but
pregabalin did not have significantly increased odds. This occurred
with co-reports of ataxia, psychotic disorder, and feeling abnormal, as
well.
4. Discussion
This study is the first post-market pharmacovigilance study to ex-
amine gabapentin reporting in the FDA Adverse Event Reporting
System and compare findings with those of a negative and a positive
control. Though gabapentin, pregabalin, and duloxetine reports all
produced signals for any abuse-related and abuse-specific adverse
events, important differences appeared when evaluating the signals
individually. Specifically, both gabapentin and pregabalin produced
significant signals for ataxia, dependence, drug abuse, increased drug
tolerance, and overdose. This is not surprising given that gabapentin
and pregabalin have similar mechanisms of action.
Another novel aspect of the current study is that we evaluated AERs
where drug abuse was indicated and assessed which effects were most
often co-reported with abuse. Drug withdrawal syndrome, euphoric
mood, auditory hallucinations, delusions, and aggression were more
often endorsed in combination with drug abuse for gabapentin or
pregabalin than for the negative control, duloxetine. While it is not
necessarily remarkable that such effects have been reported for gaba-
pentin and pregabalin (in fact several of these AEs are listed on the
drugs’ labels), what is particularly notable is that they were reported as
occurring with drug abuse, which gives insight into the psychoactive
effects that may be sought through misuse of these drugs. In a study by
Schifano and colleagues (2011), data were accumulated from online
anecdotes of recreational misuse of gabapentinoids and their results are
concordant with those identified in this study (Schifano et al., 2011).
Though pregabalin has been recognized as having abuse liability by the
U.S. Drug Enforcement Administration (U.S. Department of Justice
Drug Enforcement Administration Diversion Control Division, 2005)
Fig. 1. Adverse reporting trends by quarter, 2005–2015.
Dulox= duloxetine; GBP=gabapentin; PRG=pregabalin
Table 1
Highest frequency of adverse events by drug, 2005–2015.
Gabapentin (n) Pregabalin (n) Duloxetine (n)
Drug ineffective (9913) Pain (9962) Nausea (7354)
Pain (6784) Drug ineffective (9290) Dizziness (5941)
Nausea (6341) Dizziness (6444) Headache (5069)
Fatigue (5690) Weight increased
(5764)
Drug ineffective (5016)
Dizziness (5251) Somnolence (5059) Fatigue (4825)
Headache (4838) Nausea (4304) Drug withdrawal syndrome
(4752)
Fall (4479) Malaise (4128) Pain (4747)
Diarrhea (4408) Pain in extremity
(4055)
Insomnia (4132)
Dyspnea (4266) Fatigue (3996) Depression (4108)
Depression (3935) Feeling abnormal
(3952)
Feeling abnormal (3889)
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and the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA)-Europol (European Monitoring Centre for Drugs and Drug
Addiction, 2012), gabapentin is still assumed by the greater prescribing
community to have no abuse potential. However, the similarities be-
tween gabapentin and pregabalin in reported effects in combination
with drug abuse underscore the necessity of reevaluating the abuse
liability of gabapentin.
Interestingly, drug abuse was co-reported with ataxia with sig-
nificantly higher odds for gabapentin than duloxetine, but the effect
was not observed with pregabalin. Ataxia is a common experience of
alcohol intoxication (Diener et al., 1983; Roehrs and Roth, 2001); ga-
bapentin has produced similar effects in the human laboratory (Bisaga
and Evans, 2006) and, in a study by Peterson (2009), it was identified in
137 driving impairment cases in the State of Washington. Studies to
examine how gabapentin misuse may impact psychomotor effects are
warranted.
Gabapentin abuse signals were identified using national AE re-
porting data from the United States. However, this is not just an
American phenomenon. Our recent review (Smith et al., 2016) noted
that gabapentin misuse reports have also come from the United
Kingdom, Germany, Finland, India, South Africa, and France. Further,
in a recent paper by Chiappini and Schifano (2016) similar methods to
those used in the present study were used to examine gabapentinoid
misuse in the European Medicines Agency Suspected Adverse Drug
Reactions database. The authors determined that nearly 5 % of misuse/
abuse/dependence spontaneous AE reports were associated with ga-
bapentin (Chiappini and Schifano, 2016). Evaluation of the Canadian
Vigilance Adverse Drug Reaction Online Database also demonstrated
gabapentin misuse (Zhang and Sproule, 2015).
Though not the focus of this study, it is worth noting that the ne-
gative control, duloxetine, produced a number of significant abuse-
specific signals including drug dependence, drug diversion, intentional
drug misuse, and intentional drug overdose. This is particularly im-
portant because there are only a few published reports of duloxetine
misuse, all of which are cases of overdose (Scanlon et al., 2016), po-
tentially indicating an under-recognized or under-studied area.
The current study has several limitations. FAERS has a low spon-
taneous reporting rate, containing an average of only 6 % of all oc-
curring drug-associated AEs (Hazell and Shakir, 2006). As a result, the
incidence and prevalence of phenomena cannot be determined (de
Table 2










Dizziness 5251 (5.25) 6444 (6.59) 5941 (8.03)
Fall 4479 (4.48) 3599 (3.68) 2665 (3.60)
Somnolence 3326 (3.33) 5059 (5.17) 2379 (3.22)
Feeling abnormal 2859 (2.86) 3952 (4.04) 3889 (5.26)
Gait disturbance 2637 (2.64) 2934 (3.00) 1403 (1.90)
Confusional state 2476 (2.48) 2322 (2.37) 1838 (2.48)
Off-label use 2260 (2.26) 1870 (1.91) 2966 (4.01)
Overdose* 1374 (1.37) 918 (0.94) 777 (1.05)
Hallucination 958 (0.96) 886 (0.91) 790 (1.07)
Drug withdrawal syndrome 952 (0.95) 1495 (1.53) 4752 (6.42)
Disorientation 740 (0.74) 723 (0.74) 567 (0.77)
Drug abuse* 572 (0.57) 644 (0.66) 275 (0.37)
Aggression 570 (0.57) 501 (0.51) 706 (0.95)
Thinking abnormal 556 (0.56) 558 (0.57) 565 (0.76)
Intentional (drug) misuse* 551 (0.55) 540 (0.55) 427 (0.58)
Intentional overdose* 495 (0.50) 351 (0.36) 374 (0.51)
Drug dependence* 490 (0.49) 579 (0.59) 217 (0.29)
Delirium 404 (0.40) 355 (0.36) 244 (0.33)
Psychotic disorder 331 (0.33) 265 (0.27) 340 (0.46)
Mood altered 302 (0.30) 328 (0.34) 356 (0.48)
Hallucination, visual 282 (0.28) 255 (0.26) 200 (0.27)
Ataxia 249 (0.25) 224 (0.23) 100 (0.14)
Feeling drunk 230 (0.23) 587 (0.60) 168 (0.23)
Euphoric mood 185 (0.19) 538 (0.55) 151 (0.20)
Delusion 174 (0.17) 106 (0.11) 158 (0.21)
Hallucination, auditory 150 (0.15) 135 (0.14) 191 (0.26)
Incoherent 146 (0.15) 110 (0.11) 79 (0.11)
Multiple drug overdose* 146 (0.15) 39 (0.04) 49 (0.07)
Drug abuser 106 (0.11) 26 (0.03) 29 (0.04)
Drug tolerance 86 (0.09) 101 (0.10) 44 (0.06)
Dependence* 84 (0.08) 63 (0.06) 38 (0.05)
Substance abuse* 71 (0.07) 23 (0.02) 21 (0.03)
Dissociation 43 (0.04) 80 (0.08) 99 (0.13)
Hallucinations, mixed 43 (0.04) 55 (0.06) 46 (0.06)
Acute psychosis 28 (0.03) 11 (0.01) 20 (0.03)
Substance-induced psychotic
disorder
26 (0.03) 10 (0.01) 11 (0.01)
Drug tolerance increased 17 (0.02) 18 (0.02) 8 (0.01)
Drug diversion* 10 (0.01) 9 (0.01) 25 (0.03)
Feeling of relaxation 8 (0.01) 26 (0.03) 18 (0.02)
Elevated mood 6 (0.01) 18 (0.02) 17 (0.02)
Substance use* 5 (0.01) 5 (0.01) 1 (0.00)
Substance abuser 2 (0.00) 0 (0.00) 0 (0.00)
Rebound psychosis 1 (0.00) 0 (0.00) 0 (0.00)
Addiction* 0 (0.00) 0 (0.00) 0 (0.00)
Drug addict 0 (0.00) 0 (0.00) 0 (0.00)
Intoxication 0 (0.00) 0 (0.00) 0 (0.00)
Prescription drug use
without a prescription*
0 (0.00) 0 (0.00) 0 (0.00)
Transient psychosis 0 (0.00) 1 (0.00) 1 (0.00)
Any AR-AE 22,929 (22.93) 25,554 (26.13) 21,689 (29.32)
AR-AE: abuse-related adverse event. Note: Percentages are out of the total for
each case drug. *Denotes an abuse-specific adverse event.
Table 3
Frequency of co-reporting of an abuse-specific adverse event by case drug and










Somnolence 262(7.6) 269(9.3) 130(6.3)
Drug withdrawal syndrome 215(6.3) 163(5.6) 172(8.4)
Confusional state 200(5.8) 118(4.1) 104(5.1)
Fall 187(5.4) 128(4.4) 97(4.7)
Dizziness 175(5.1) 170(5.8) 140(6.8)
Feeling abnormal 144(4.2) 171(5.9) 126(6.1)
Off-label use 99(2.9) 110(3.8) 114(5.6)
Gait disturbance 86(2.5) 96(3.3) 51(2.5)
Aggression 82(2.4) 78(2.7) 46(2.2)
Hallucination 75(2.2) 53(1.8) 48(2.3)
Drug abuser 62(1.8) 13(0.4) 8(0.4)
Delirium 58(1.7) 25(0.9) 24(1.2)
Euphoric mood 54(1.6) 77(2.6) 9(0.4)
Thinking abnormal 52(1.5) 32(1.1) 29(1.4)
Disorientation 46(1.3) 37(1.3) 29(1.4)
Ataxia 45(1.3) 19(0.7) 6(0.3)
Psychotic disorder 43(1.3) 13(0.4) 20(1.0)
Drug tolerance 29(0.8) 28(1.0) 7(0.3)
Delusion 26(0.8) 19(0.7) 9(0.4)
Mood altered 26(0.8) 27(0.9) 19(0.9)
Hallucination, auditory 20(0.6) 15(0.5) 5(0.2)
Hallucination, visual 16(0.5) 14(0.5) 8(0.4)
Incoherent 16(0.5) 6(0.2) 8(0.4)
Feeling drunk 10(0.3) 18(0.6) 3(0.1)
Drug tolerance increased 9(0.3) 5(0.2) 3(0.1)
Hallucinations, mixed 4(0.1) 10(0.3) 3(0.1)
Feeling of relaxation 1(0.0) 5(0.2) 1(0.0)
Substance-induced psychotic disorder 1(0.0) 1(0.0) 0(0.0)
Substance abuser 1(0.0) 0(0.0) 0(0.0)
Dissociation 0(0.0) 1(0.0) 3(0.1)
Drug addict 0(0.0) 0(0.0) 0(0.0)
Elevated mood 0(0.0) 3(0.1) 1(0.0)
Intoxication 0(0.0) 0(0.0) 0(0.0)
Acute psychosis 0(0.0) 0(0.0) 1(0.0)
Rebound psychosis 0(0.0) 0(0.0) 0(0.0)
Transient psychosis 0(0.0) 0(0.0) 0(0.0)
Note: Frequencies and percentages exclude any cases where case drugs were co-
reported.
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Boer, 2011; Rodriguez et al., 2001). However, the abuse signals de-
tected herein provide a critical indication that further examination is
required, especially in the context of a growing number of case reports
of gabapentin misuse. Also, many external factors affect FAERS re-
porting such as the “notoriety effect” (Pariente et al., 2007), an uptick
in reporting resulting from a safety alert, or the “ripple effect” where
reporting is accelerated following notoriety of a drug in the same class
(Pariente et al., 2007), among others (Hartnell and Wilson, 2004;
Hochberg et al., 2009; Wang et al., 2010). By cumulating data over the
11-year study period, we partially mitigated the impact of fluctuations
present in the data. Importantly, some of the signals detected could
have been confounded by the populations for which the drugs are
prescribed (e.g., gabapentinoids prescribed off-label for mood dis-
orders) as well as due to interactions with concomitant medications.
However, the purpose of this study was not to assess cause-and-effect,
but rather to corroborate described effects in case reports and provide
hypotheses for future controlled clinical studies. Similarly, this study
did not identify the primary suspect drug for each adverse event, which
could provide further elucidation on the effects experienced; this is an
important area for additional investigation.
5. Conclusions
We identified abuse-related signals for gabapentin and elucidated
several CNS effects that may be associated with its abuse. Future stu-
dies, including large-scale controlled pharmacological studies are
needed to determine whether the CNS effects are a direct result of ga-
bapentin. Prescribers should be aware of gabapentin’s abuse liability
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AS-AE * Drug withdrawal syndrome 6.55 (5.24 - 8.19) 3.08 (2.44 - 3.87) REF
AS-AE * Euphoric mood 5.45 (2.70 - 12.26) 2.47 (1.27 - 5.42) REF
AS-AE * Auditory hallucination 4.57 (1.79 - 14.04) 4.28 (1.61 - 13.46) REF
AS-AE * Drug abuser 3.01 (1.26 - 7.82) 2.45 (0.81 - 7.78) REF
AS-AE * Ataxia 2.85 (1.26 - 7.68) 1.34 (0.55 - 3.79) REF
AS-AE * Delusion 2.36 (1.10 - 5.49) 3.33 (1.48 - 8.06) REF
AS-AE * Drug tolerance 2.25 (0.93 - 6.06) 1.90 (0.79 - 5.10) REF
AS-AE * Feeling drunk 2.05 (0.61 - 9.25) 1.61 (0.53 - 6.92) REF
AS-AE * Aggression 1.98 (1.35 - 2.92) 2.47 (1.68 - 3.66) REF
AS-AE * Psychotic disorder 1.96 (1.14 - 3.48) 0.77 (0.37 - 1.57) REF
AS-AE * Feeling of relaxation 1.95 (0.07 - 54.16) 3.78 (0.54 - 76.08) REF
AS-AE * Drug tolerance increased 1.72 (0.31 - 10.93) 0.60 (0.10 - 3.79) REF
AS-AE * Thinking abnormal 1.52 (0.96 - 2.47) 1.03 (0.61 - 1.73) REF
AS-AE * Mood altered 1.37 (0.75 - 2.57) 1.47 (0.80 - 2.74) REF
AS-AE * Feeling abnormal 1.31 (1.02 - 1.69) 1.26 (0.99 - 1.61) REF
AS-AE * Delirium 1.24 (0.76 - 2.10) 0.64 (0.35 - 1.16) REF
AS-AE * Somnolence 1.24 (0.99 - 1.55) 0.91 (0.73 - 1.14) REF
AS-AE * Confusional state 1.20 (0.94 - 1.55) 0.82 (0.62 - 1.08) REF
AS-AE * Dizziness 1.19 (0.94 - 1.50) 1.05 (0.83 - 1.32) REF
AS-AE * Visual hallucination 1.16 (0.50 - 2.92) 1.29 (0.54 - 3.29) REF
AS-AE * Mixed hallucinations 1.15 (0.24 - 6.16) 2.90 (0.82 - 13.63) REF
AS-AE * Hallucination 1.08 (0.74 - 1.58) 0.90 (0.60 - 1.36) REF
AS-AE * Disorientation 1.02 (0.63 - 1.67) 0.93 (0.56 - 1.55) REF
AS-AE * Fall 0.94 (0.73 - 1.22) 0.90 (0.68 - 1.19) REF
AS-AE * Off-label use 0.93 (0.70 - 1.22) 1.46 (1.11 - 1.92) REF
AS-AE * Incoherent 0.90 (0.37 - 2.32) 0.47 (0.15 - 1.41) REF
AS-AE * Gait disturbance 0.73 (0.51 - 1.05) 0.82 (0.58 - 1.18) REF
AS-AE * Elevated mood – 2.98 (0.34 - 64.10) REF
AS-AE * Dissociation – 0.38 (0.02 - 3.01) REF
AE: adverse event; OR: odds ratio; 95 % CI: 95 % confidence interval; AS-AE: abuse-specific adverse event; REF: referent group.
Note: Missing results correspond to occasions where no events were reported.
Boldface indicates a significant result at p < .05.
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